Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
5.27
-0.22 (-4.01%)
Mar 6, 2026, 4:00 PM EST - Market closed
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
1.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 257.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 400.00K | 346.00K | 640.74% |
| Dec 31, 2015 | 54.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | 300.00K | -200.00K | -40.00% |
| Dec 31, 2008 | 500.00K | - | - |
| Dec 31, 2007 | 500.00K | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Monte Rosa Therapeutics | 181.54M |
| Day One Biopharmaceuticals | 158.18M |
| Immatics | 56.67M |
| EyePoint | 31.37M |
| Zenas BioPharma | 15.00M |
| Capricor Therapeutics | 11.13M |
| AtaiBeckley | 4.09M |
SVRA News
- 2 days ago - Savara Announces Participation in 2026 Citizens Life Sciences Conference - Business Wire
- 14 days ago - Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 21 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 4 weeks ago - Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire
- 5 weeks ago - Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* - Business Wire
- 7 weeks ago - Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* - Business Wire
- 2 months ago - Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire